CSL Ltd makes $11.7 billion offer to acquire Vifor Pharma

14 December 2021
cslbig

After a few of days speculation and rumors, Australia-headquartered biotech CSL Limited (ASX: CSL) today confirmed it has entered into a definitive agreement to acquire Switzerland-based Vifor Pharma (VTX: FIFoN), a specialty pharmaceutical company with leadership in iron deficiency, nephrology and cardio-renal therapies.

CSL has made an offer of $179.25 (167 Swiss francs) per share, payable in US dollars, a premium of 61% to Vifor’s unaffected closing price on December 1, for an aggregate equity value for Vifor Pharma of $ 11.7 billion/10.9 billion francs. The tender is currently expected to commence around January 18, 2022 and the transaction is expected to complete around mid-2022.

Vifor’s shares, which had already risen earlier this month on the basis of the rumors, were up 11.8% at 156.90 francs by late afternoon today.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical